Thomas T Tibbitts
Thomas T. Tibbitts, Ph. D. founded DTI in May 2020 to integrate the latest technologies in genomics, biology and computing to bring new medicines to patients suffering with respiratory infections and diseases of the lung. Dr. Tibbitts, serving as its CEO and Head of Research and Development, has over twenty years experience in the pharmaceutical industry. Most recently, Dr. Tibbitts served as Senior Vice President for Computational Research at Goldfinch Bio, where he launched the Kidney Genome Atlas and built a world-class team for sequencing thousands of patients and integrating transcriptomics and epigenetics for the discovery of novel genetic targets in kidney disease. He was part of the initial team that launched Goldfinch with $55M series A funding in 2016 at Third Rock Ventures. At Infinity Pharmaceuticals, Thomas contributed to multiple drug programs for over a decade which lead to Copiktra (duvelisib), a medication approved to treat chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) and IPI-549, currently in clinical development for the treatment of advanced urothelial cancer. Dr. Tibbitts holds a PhD in Biophysics from Brandeis University and has numerous patents and peer-reviewed publications in drug discovery, oncology, enzymology and structural biology.